{
    "nctId": "NCT04734262",
    "briefTitle": "A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",
    "officialTitle": "A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 98,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR) by Investigator in Cohort A, Cohort B and Cohort C",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Able to provide written informed consent and can understand and agree to comply with the requirements of the study and the schedule of assessments\n* Age \u2265 18 years on the day of signing the ICF (or the legal age of consent in the jurisdiction in which the study is taking place)\n* Histologically confirmed diagnosis of TNBC characterized by estrogen-receptor negative (ER-), progesterone receptor negative (PR-) and human epidermal growth factor-2 receptor negative (HER2-);\n* \u2264 3 prior lines of systemic therapy\n* For patients refractory/resistant to anti-PD-1/PD-L1 antibodies, there should be no anti-PD-1/PD-L1 treatment-related toxicity from prior therapies\n* Previously untreated for metastatic setting or recurred/metastasized after surgery for locally recurrent or metastatic breast cancer (cohort C), and the time from previous neo-/adjuvant therapy to recurrence met the following requirements: \u2265 6 months interval between the end of neo-/adjuvant paclitaxel-based treatment and the onset of recurrence/metastasis; \u2265 6 months interval between the end of neo-/adjuvant anti-angiogenic treatment and the onset of recurrence/metastasis; \u2265 6 months interval between the end of neo-/adjuvant immunotherapy and recurrence/metastasis\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ function\n* Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study, and \u2265 120 days after the last dose of study drug(s), and have a negative serum pregnancy test \u2264 7 days of first dose of study drug(s)\n* Nonsterile males must be willing to use a highly effective method of birth control for the duration of the study and for \u2265 120 days after the last dose of study drug(s)\n\nExclusion Criteria:\n\n* Active leptomeningeal disease or uncontrolled brain metastasis\n* Active autoimmune diseases or history of autoimmune diseases that may relapse\n* Any active malignancy \u2264 2 years\n* Severe chronic or active infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to first dose of study drug(s)\n* History of interstitial lung disease, noninfectious pneumonitis or uncontrolled diseases including pulmonary fibrosis, acute lung diseases, etc\n* Known history of human immunodeficiency virus (HIV) infection\n* Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers\n* Any major surgical procedure requiring general anesthesia \u2264 28 days before the first dose of study drug(s)\n* Prior allogeneic stem cell transplantation or organ transplantation\n* Inadequately controlled hypertension (defined as systolic blood pressure \\> 150 mmHg and/or diastolic blood pressure \\> 100 mmHg)\n* Bleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (INR) monitoring\n* Any systemic chemotherapy within 28 days of the first dose of study drug(s) or hormone therapy, targeted therapy, or any investigational therapies Toxicities (as a result of prior anticancer therapy) that have not recovered to baseline or stabilized, except for AEs not considered a likely safety risk (eg, alopecia, neuropathy, and specific laboratory abnormalities)\n* Inability to swallow capsules or disease significantly affecting gastrointestinal function\n* Pregnant or breastfeeding woman NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}